Intrasense — Regulatory Filings 2021

Apr 1, 2021

Montpellier, France, April 1 st, 2021 – 08:00am CEST

New Myrian platform launch, enriched with many new clinical features dedicated to stroke, breast cancer and cardiovascular pathologies

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and Myrian® designer, is pleased to present the new version 2.9, with a focus on new clinical features.

Brain perfusion CT exams now supported

The new Myrian XP-Brain Perfusion CT Clinical App enables CT brain perfusion examinations. This solution meets a strong clinical need, particularly in the context of stroke management, which is a public health priority. With around 150,000 new cases per year¹ in France, it is the leading cause of acquired disability and the second leading cause of death in women, and the third in men. Time is a major factor for patients with suggestive signs of stroke who must have brain imaging as quickly as possible in order to define the most suitable treatment in a very short time.

Myrian XP-Brain Perfusion CT allows a fully automatic mismatch calculation in a few seconds, allowing significant savings in diagnostic time. In addition, this new clinical application also has tools to perform tumor analyzes.

The certification process for CE marking is underway.

Novelties for cardiovascular and breast Imaging

Myrian XP-Cardiac benefits from improvements as well as new features, concerning the workflow, allowing user to save time in analyzing his exams and in the comfort of use. It is now possible to start working on an exam during the automatic segmentation step. New features like automatic ostium detection and stenosis libraries are available.

Press release

Intrasense offers the most comprehensive breast imaging solution on the market. Breast cancer remains the most common cancer for women and is the subject of screening strategies in most developed countries. Intrasense solution allows patient care throughout the entire course of care. Thereby, Intrasense meets a strong clinical need by offering a unified and comprehensive solution, from screening to diagnosis.

Intrasense's development choices in the oncology segment now allow the company to have a very complete offer around these different pathologies. Solutions offered by the company integrate the entire patient care pathway from screening to diagnosis, including follow-up. This oncology application portfolio is among the best performing in a growing market segment.

¹Source: https://solidarites-sante.gouv.fr/soins-et maladies/maladies/maladies-cardiovasculaires/accident-vasculaire-cerebral avc/article/l-accident-vasculaire-cerebral

About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device named Myrian®, a software platform facilitating and ensuring diagnosis, decision-making and therapeutic follow-up. Thanks to Myrian®, more than 1000 hospitals and clinics spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner…). Enriched with expert clinical modules dedicated to specific pathologies and organs, Myrian® provides a universal medical image processing solution which can be fully integrated into any healthcare information system. Intrasense has more than 40 employees among which 15 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and has invested more than 10 million euros in Research & Development since its creation. More information on: www.intrasense.fr

Contacts

Intrasense Jérémy Peyron Marketing & Communication manager 1231 avenue du Mondial 98, 34000 Montpellier, FRANCE Tel: +334 67 130 130 investor@intrasense.fr

NewCap Investor Relations and Financial Communication Louis Tilquin Paris, FRANCE Tel: +331 44 71 20 43 intrasense@newcap.eu